Showing posts with label non-metastatic recurrence. Show all posts
Showing posts with label non-metastatic recurrence. Show all posts

Sunday, September 11, 2022

Short-term androgen annihilation in non-metastatic recurrent men delays progression

 A difficult question for patients who still having rising PSA after prostatectomy and salvage radiation is: Is there any advantage to starting advanced hormone therapy before metastases are visible?

Rahul Aggarwal presented the early results of the PRESTO trial. Patients (n=504) were chosen who had the following characteristics:

  • Failed prostatectomy and salvage radiation (85%). Half of those who had salvage radiation, had adjuvant ADT at the time
  • PSA>0.5 ng/ml
  • PSA doubling time (PSADT) ≤ 9 month
  • no metastases on conventional imaging (bone scan/CT/MRI)

Patients were randomly assigned to one year of any of the following treatments:

  1. ADT only
  2. ADT+apalutamide
  3. ADT+abiraterone+apalutamide

With follow-up of 21 months, biochemical progression-free survival (bPFS, PSA stayed under 0.2 ng/ml) was:

  • 20 mos. in Group A
  • 25 mos. in Group B (48% improvement vs Group A)
  • 26 mos. in Group C  (52% improvement vs Group A)
  • No significant differences attributable to PSADT
  • Group C wasn't significantly different from Group B (Zytiga added little)

Other findings:

  • Testosterone recovered in 4-5 months in all groups
  • More hypertension with abiraterone

Other trials have looked at adding a limited term of 2nd line hormonal medicines when there is rapid PSADT but before metastases have been discovered on conventional imaging.

  • Spetsieris et al. added abiraterone for 8 months. Afterwards, bPFS was 27 mos vs 20 mos. for ADT-only.
  • Madan et al. reported substantial PSA control with intermittent use (two 3-month cycles) of enzalutamide alone without ADT. PSA didn't rise for 6-7 months after the first and second cycles.

With detection of metastases with PSMA PET scans, the advantage of early intervention will become clearer. There is also a clearer advantage for men with a higher Decipher score. It is likely that even intermittent use will be advantageous. Men with rapid PSADT after salvage radiation should consider a short-term intervention with one of the advanced hormonals.